Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 02, 2015 11:34 AM ET

Pharmaceuticals

Company Overview of Taisho Pharmaceutical Co., Ltd.

Company Overview

Taisho Pharmaceutical Co., Ltd. manufactures and sells over-the-counter (OTC) medicines and health-related products. The company offers its products in the areas of CNS, diabetes, immunology/allergy, and infectious diseases; and provides self-medication products, such as Rx-to-OTC switch drugs, eye drops, cold remedy medication products, gastrointestinal medication products, energy drinks, hair re-growth treatment medication products, and foods for specified health use. It also provides prescription pharmaceutical products, such as macrolide antibiotics, injectable antibiotics, peripheral vasodilators, nonsteroidal anti-inflammatory drugs, and infection and inflammation/immune-related produc...

3-24-1, Takada

Toshima-ku

Tokyo,  170-8633

Japan

Founded in 2011

Phone:

81 3 3985 1111

Fax:

81 3 3985 8627

Key Executives for Taisho Pharmaceutical Co., Ltd.

President and Representative Director
Executive Vice President and Director
Executive Director
Senior Executive Officer and Director
Corporate Adviser and Director
Age: 78
Compensation as of Fiscal Year 2015.

Taisho Pharmaceutical Co., Ltd. Key Developments

Taisho Pharmaceutical Co., Ltd. Announces Encouraging Results from Phase III Osteoarthritis Trials

Taisho Pharmaceutical Co., Ltd. has announced encouraging results from two Phase III clinical trials with the anti-inflammatory analgesic patch formulation containing S-flurbiprofen, or TT-063, in patients with osteoarthritis. The clinical trials investigated the efficacy of applying TT-063 for two weeks, targeting 633 patients with osteoarthritis of the knee joint. The patients were divided into a group of patients to whom TT-063 was administered, and a group of patients to whom a flurbiprofen gel patch (FP) was administered as a control drug. The trials compared the two groups. The primary endpoint of the study was the change in the assessment of pain when standing. The change in this pain assessment before and after application of the patch was 40.9 mm for the TT-063 group and 30.6 mm for the FP group. As a result, the TT-063 group demonstrated significantly superior efficacy relative to the FP group. In other areas, the TT-063 group demonstrated clinically higher efficacy in terms of the assessment of pain when walking (VAS) and clinical symptoms, compared with the FP group. As a long-term trial, the clinical trials investigated the continuous application of TT-063 for 52 weeks, targeting 201 patients with osteoarthritis. The trials showed that 80% of the patients were able to continuously apply TT-063 over the trial period. Therefore, TT-063 was confirmed to possess good tolerability even during long-term use.

Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. Announce Positive Results from Phase III Osteoporosis Trial

Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd., have announced positive results from Japanese Phase III clinical trial of a bisphosphonate antiresorptive agent, ibandronate sodium hydrate oral agent, which is currently co-developed by Chugai and Taisho in Japan for the anticipated indication of osteoporosis. The MOVEST study, a randomized, multi center, double-blind, parallel group, controlled study, was conducted in approximately 400 patients (over 55 years of age) with osteoporosis to assess efficacy and safety of ibandronate oral formulation 100mg against ibandronate sodium hydrate injection [brand name: Bonviva IV Injection 1 mg Syringe (ibandronate injection)]. The increase in bone mineral density (BMD) of the lumbar spine (L2-L4) (percentage of relative change from baseline) at twelve month, the study's primary endpoint, was 5.22% for ibandronate oral formulation, and 5.34% [ 95% CI: 4.78% - 5.90% ] for ibandronate injection, respectively. The difference between the rate of change for ibandronate injection group of ibandronate oral formulation group (least squeares meane) was -0.23. It met the protocol criteria, a non-inferiority of ibandronate oral formulation to ibandronate injection has been demonstrated. The secondary endpoints of BMD gains in femur and inhibition on bone metabolic markers also showed similar effects between the two groups. No new safety signals were observed in the study. The safety profile was consistent with the previous overseas study results, and well tolerability of ibandronate oral formulation in osteoporotic patients was observed. Chugai filed a new drug application to the Ministry of Health, Labour and Welfare in February 2015, based on above and other data. Chugai and Taisho have been co-developing ibandronate oral formulation and Bonviva IV Injection in Japan as new treatment options for osteoporosis that improve adherence and offer patients wider choice of administration routes in Japan. Chugai and Taisho Toyama Pharmaceutical Co., Ltd. have been co-marketing Bonviva IV Injection, developed ahead of ibandronate oral formulation, since August, 2013 after Chugai obtained approval for osteoporosis indication in June, 2013. Following Bonviva IV Injection, Chugai and Taisho are determined to make efforts to obtain early approval of ibandronate oral formulation, a monthly oral agent and supply to patients and healthcare professionals.

Vernalis plc Enters into Research Collaboration with Taisho Pharmaceutical

Vernalis plc announced that it has entered into a drug discovery collaboration with Taisho Pharmaceutical Co., Ltd., utilizing Vernalis' fragment and structure-based drug discovery platform against an undisclosed target for the development of potential antibiotic agents.

Similar Private Companies By Industry

Company Name Region
Nihon Seiyaku Kogyo Co., Ltd. Asia
Japan Health Summit, Inc. Asia
Nippon Supplement, Inc. Asia
Pharma Eight Co. Ltd. Asia
Maruko Pharmaceutical Co., Ltd. Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Taisho Pharmaceutical Co., Ltd., please visit www.taisho.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.